Disease-modifying therapies (DMTs) are primarily effective through immunomodulation, in that they target relapse prevention, said Burcu Zeydan, MD, assistant professor of neurology, assistant professor of radiology, at Mayo Clinic.
Aging has a noticeable effect on why disease-modifying therapies become less effective as patients get older, especially when you account for the decreases in both CNS reserve and postrelapse recovery potential, explained Burcu Zeydan, MD,assistant professor of neurology, assistant professor of radiology, at Mayo Clinic.
Transcript
Why do disease-modifying therapies (DMTs) lose efficacy as patients with MS age?
Well, when we consider aging-related observations about relapse recovery progression and CNS reserve in multiple sclerosis, it is not surprising that the disease-modifying therapies lose efficacy as patients with MS age. As the CNS reserve decreases with age, the postrelapse recovery potential decreases with age as well. Most importantly, the clinical and subclinical relapses become less frequent with age, while evolution to progressive illness increases with age. So, the existing DMTs are primarily effective through immunomodulation. They target relapse prevention, and they are not specifically meant to prevent progression.
It seems like the optimal window for existing numbered literary DMTs is earlier in life, when the disease is more likely to be active, by preventing some symptomatic relapses and asymptomatic subclinical activity. On the other hand, the currently available DMTs seem to lose efficacy with aging. We know that aging plays a major role in the development of a progressive disease course, with neurodegeneration becoming more prominent and severe disability being closely related to progressive illness.
In a 2017 meta analysis from the NIH, all randomized and blinded MS clinical trials were evaluated. And the efficacy of the DMTs was clearly found to be lowered in older patients compared to younger patients with MS. Although the authors emphasized that efficacy of immunomodulatory DMTs is on disability worsening, strongly decreased with advancing age, they also emphasize that the patient's specific genetic and environmental factors are still important in making treatment decisions.
Overall, the decline in the efficacy of DMTs with older age in MS seems to reflect the impact of aging on the relationship between reserves, relapses, recovery, and progressive MS z-scores mechanisms.
Looking Back on ISPOR 2024: Hot Policy Topics, Welcome Focus on Employers, and More
May 10th 2024Kimberly Westrich, MA, chief strategy officer of the National Pharmaceutical Council, reflects on the most valuable learnings from the 2024 meeting of ISPOR—The Professional Society for Health Economics and Outcomes Research, including lively discussions of the Inflation Reduction Act and workshops on value assessment.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Posters Characterize DMD Caregiver Experiences, Impact of Gene Therapy on Caregiving Demands
May 10th 2024Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.
Read More
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Budesonide-Based Triple Therapy Shows Best Benefit Over Dual Therapy for COPD
May 8th 2024The triple therapy of budesonide, glycopyrrolate, and formoterol fumarate showed the greatest incremental net benefit among a series of triple therapy medications that were evaluated against dual therapy for chronic obstructive pulmonary disease (COPD), according to an analysis presented at ISPOR.
Read More